Article

ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclib

2026-02-17

Abstract excerpt

<title>Abstract</title> <p>Background Palbociclib, combined with endocrine therapy (ET), is widely used for hormone receptor (HR)-positive, HER2-negative advanced breast cancer, but severe neutropenia is common, particularly in Asian populations. Pharmacogenetic determinants beyond ABCB1 remain insufficiently characterized, and real-world data in Japanese patients are scarce. Methods A total of 84 patients were i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 385f780a-abef-5b37-9e59-ac4bffd3564c
DOI: 10.21203/rs.3.rs-8780668/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibDOI 10.21203/rs.3.rs-8780668/v1Read

ABCG2 genetic polymorphism as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity Read

ABCG2 genetic variant as a predictor of severe neutropenia in Japanese patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with palbociclib: an exploratory real-world studySemantic proximity Read

Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study.Semantic proximity Read

Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3Semantic proximity Read

Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.Semantic proximity Read

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.Semantic proximity Read

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclibSemantic proximity Read

ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.Semantic proximity Read

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.Semantic proximity Read

Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.Semantic proximity Read

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity Read

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.Semantic proximity Read